|
September 23, 2015
The left is up in arms over the pharmaceutical CEO who raised prices for a drug mostly used by AIDS patients by more than 5,000 percent, but experts CNBC interviewed said regulatory barriers helped make it possible.
Founder and CEO of Turing…